ASRT
Price
$0.80
Change
-$0.01 (-1.23%)
Updated
Sep 5 closing price
Capitalization
76.78M
60 days until earnings call
COLL
Price
$38.32
Change
-$0.91 (-2.32%)
Updated
Sep 5 closing price
Capitalization
1.21B
60 days until earnings call
Interact to see
Advertisement

ASRT vs COLL

Header iconASRT vs COLL Comparison
Open Charts ASRT vs COLLBanner chart's image
Assertio Holdings
Price$0.80
Change-$0.01 (-1.23%)
Volume$57.03K
Capitalization76.78M
Collegium Pharmaceutical
Price$38.32
Change-$0.91 (-2.32%)
Volume$470.06K
Capitalization1.21B
ASRT vs COLL Comparison Chart in %
Loading...
ASRT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASRT vs. COLL commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASRT is a Hold and COLL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (ASRT: $0.80 vs. COLL: $38.32)
Brand notoriety: ASRT and COLL are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ASRT: 24% vs. COLL: 127%
Market capitalization -- ASRT: $76.78M vs. COLL: $1.21B
ASRT [@Pharmaceuticals: Generic] is valued at $76.78M. COLL’s [@Pharmaceuticals: Generic] market capitalization is $1.21B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASRT’s FA Score shows that 0 FA rating(s) are green whileCOLL’s FA Score has 1 green FA rating(s).

  • ASRT’s FA Score: 0 green, 5 red.
  • COLL’s FA Score: 1 green, 4 red.
According to our system of comparison, COLL is a better buy in the long-term than ASRT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASRT’s TA Score shows that 4 TA indicator(s) are bullish while COLL’s TA Score has 4 bullish TA indicator(s).

  • ASRT’s TA Score: 4 bullish, 4 bearish.
  • COLL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ASRT is a better buy in the short-term than COLL.

Price Growth

ASRT (@Pharmaceuticals: Generic) experienced а -4.47% price change this week, while COLL (@Pharmaceuticals: Generic) price change was -1.24% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ASRT is expected to report earnings on Nov 06, 2025.

COLL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($1.21B) has a higher market cap than ASRT($76.8M). COLL YTD gains are higher at: 33.752 vs. ASRT (-8.415). COLL has higher annual earnings (EBITDA): 347M vs. ASRT (-8.66M). COLL has more cash in the bank: 222M vs. ASRT (98.2M). ASRT has less debt than COLL: ASRT (39.9M) vs COLL (829M). COLL has higher revenues than ASRT: COLL (707M) vs ASRT (117M).
ASRTCOLLASRT / COLL
Capitalization76.8M1.21B6%
EBITDA-8.66M347M-2%
Gain YTD-8.41533.752-25%
P/E RatioN/A36.15-
Revenue117M707M17%
Total Cash98.2M222M44%
Total Debt39.9M829M5%
FUNDAMENTALS RATINGS
ASRT vs COLL: Fundamental Ratings
ASRT
COLL
OUTLOOK RATING
1..100
6889
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
9752
PRICE GROWTH RATING
1..100
5340
P/E GROWTH RATING
1..100
997
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ASRT's Valuation (67) in the Pharmaceuticals Major industry is in the same range as COLL (68) in the Pharmaceuticals Other industry. This means that ASRT’s stock grew similarly to COLL’s over the last 12 months.

COLL's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for ASRT (100) in the Pharmaceuticals Major industry. This means that COLL’s stock grew somewhat faster than ASRT’s over the last 12 months.

COLL's SMR Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for ASRT (97) in the Pharmaceuticals Major industry. This means that COLL’s stock grew somewhat faster than ASRT’s over the last 12 months.

COLL's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as ASRT (53) in the Pharmaceuticals Major industry. This means that COLL’s stock grew similarly to ASRT’s over the last 12 months.

COLL's P/E Growth Rating (7) in the Pharmaceuticals Other industry is significantly better than the same rating for ASRT (99) in the Pharmaceuticals Major industry. This means that COLL’s stock grew significantly faster than ASRT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASRTCOLL
RSI
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
65%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
71%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 5 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
64%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ASRT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCEEX9.920.14
+1.43%
Goldman Sachs Clean Energy Income R6
NBMLX19.390.08
+0.41%
Neuberger Berman Mid Cap Growth Inst
SUHIX43.510.13
+0.30%
DWS Health and Wellness Inst
TGCNX25.550.01
+0.04%
TCW Concentrated Large Cap Growth N Cl
JGAQX38.90-0.13
-0.33%
JPMorgan Value Advantage R2

ASRT and

Correlation & Price change

A.I.dvisor tells us that ASRT and RGEDF have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ASRT and RGEDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASRT
1D Price
Change %
ASRT100%
-1.19%
RGEDF - ASRT
31%
Poorly correlated
N/A
SNOA - ASRT
28%
Poorly correlated
+4.42%
COLL - ASRT
27%
Poorly correlated
-2.32%
LFCR - ASRT
24%
Poorly correlated
-5.16%
CPHI - ASRT
24%
Poorly correlated
+16.32%
More

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-2.32%
AMPH - COLL
41%
Loosely correlated
+0.79%
AMRX - COLL
39%
Loosely correlated
+0.73%
VTRS - COLL
37%
Loosely correlated
+1.65%
ALKS - COLL
35%
Loosely correlated
+3.53%
ANIP - COLL
34%
Loosely correlated
-0.68%
More